Compare CRESY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRESY | ARVN |
|---|---|---|
| Founded | 1936 | 2015 |
| Country | Argentina | United States |
| Employees | 2889 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.2M | 658.2M |
| IPO Year | N/A | 2018 |
| Metric | CRESY | ARVN |
|---|---|---|
| Price | $11.69 | $7.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $15.05 |
| AVG Volume (30 Days) | 273.7K | ★ 694.3K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 8.14% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.92 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.39 | $6.06 |
| 52 Week High | $14.21 | $14.22 |
| Indicator | CRESY | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 37.96 |
| Support Level | $10.90 | $7.35 |
| Resistance Level | $12.26 | $10.18 |
| Average True Range (ATR) | 0.58 | 0.42 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 42.31 | 31.43 |
Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.